Trump's 100% Tariffs on Branded Pharmaceuticals Trigger Sharp Decline in Indian Pharma Stocks
Key Insights
President Trump announced 100% tariffs on all imported branded and patent-protected medicines (search) to the US starting October 1, 2025, unless companies are actively building manufacturing plants in America.
Indian pharmaceutical stocks plummeted up to 5% following the announcement, with Sun Pharma hitting its yearly low and the Nifty Pharma Index declining 2.54%.
The policy could significantly impact Indian pharma companies that generate substantial revenue from US exports, potentially affecting over $233 billion of US pharma imports while exempting generic drug exporters.
Indian pharmaceutical stocks experienced sharp declines on Friday, September 26, following President Donald Trump's announcement of imposing 100% tariffs on branded and patent-protected medicines (search) imported to the United States. The policy, set to take effect October 1, 2025, sent shockwaves through the pharmaceutical sector, with major Indian companies seeing significant market value erosion.
Market Impact Across Major Pharma Companies
Sun Pharma suffered the steepest decline, plunging 5% to ₹1,547, marking its lowest level this year. The broad-based selloff extended across the sector, with Biocon falling 3.3% to ₹344 and Zydus Lifesciences decreasing 2.8% to ₹990.
Other major pharmaceutical companies also experienced substantial losses. Aurobindo Pharma dropped 2.4% to ₹1,070, while Dr. Reddy's fell 2.3% to ₹1,245.30. Both Lupin and Cipla decreased by 2%, closing at ₹1,923.30 and ₹1,480, respectively. Torrent Pharma showed the smallest decline at 1.5%, reaching ₹3,480.65.
By 9:30 am, the Nifty Pharma Index was down 2.54%, reflecting the sector-wide impact of the announcement.
Trump's Tariff Policy Details
Trump announced the policy on his Truth Social platform, stating: "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America."
The policy includes specific exemptions for companies actively engaged in US manufacturing. According to Trump's post, "IS BUILDING" is defined as "breaking ground" and/or "under construction." He clarified that "There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started."
Implications for Indian Pharmaceutical Industry
The announcement poses significant challenges for Indian drug companies, as the U.S. market accounts for a substantial portion of revenue for companies including Sun Pharma, Dr. Reddy's, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences.
Additional pharmaceutical entities such as Biocon, Syngene, Gland Pharma, and Piramal Pharma also depend heavily on exports of generic medicines (search), biosimilars (search), and specialty medicines (search) to the United States. These companies could face reduced profits or be required to invest in building manufacturing plants in the US, which represents a time-consuming and expensive undertaking.
Expert Analysis and Market Outlook
Banking and market expert Ajay Bagga provided perspective on the policy's potential impact, telling news agency PTI that Trump's decision "has added a new layer of uncertainty." He noted that "The 100 per cent tariffs announced on branded pharma imports can potentially impact over USD 233 billion of US pharma exports."
However, Bagga offered some reassurance for the Indian pharmaceutical sector, stating that "Indian generic drug exporters should be exempt for now, which safeguards most of the USD 12 billion of Indian pharma exports to the US."
Strategic Considerations Moving Forward
Analysts anticipate that stocks of companies with significant dependence on U.S. sales may face continued pressure in the near term. Conversely, Indian companies focused primarily on the domestic market might benefit from potential shifts in global supply chains.
The policy aims to strengthen domestic US production while reducing dependence on international sources for premium, patent-protected medications. Industry specialists and the administration are expected to closely monitor the situation, as this policy may fundamentally reshape trade patterns in the global pharmaceutical sector.